AVECTAS Leads €7.23 million Consortium Awarded Part Funding From Ireland’s Disruptive Technologies Innovation Fund
Funding to develop high throughput cell engineering technology to manufacture off the shelf cell therapies
Project, led by Avectas in partnership with Bluebridge Technologies and National Institute for Bioprocessing Research and Training (NIBRT), would support Ireland s goal of being at the forefront of cell therapy manufacturing
Kildare, Ireland and Cambridge, MA, USA … Friday 23 April 2021. Irish cell engineering company, Avectas, is leading a consortium which will invest €7.23 million, including €4.4 million awarded under the Irish Government’s Disruptive Technology Innovation Fund (DTIF), to develop a high-throughput scale of its proprietary cell engineering platform Solupore®. With consortium partners Bluebridge Technologies and NIBRT, the project expands Avectas development towards commercialising an advanced large-scale, digitalised cell engin
AVECTAS dirige un consortium de 7,23 millions d euros financé en partie par le Disruptive Technologies Innovation Fund prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
DUBLIN, April 22, 2021 /PRNewswire/ Irish cell engineering company, Avectas, is leading a consortium which will invest €7.23 million, including €4.4 million awarded under the Irish Government s Disruptive Technology Innovation Fund (DTIF), to develop a high-throughput scale of its proprietary cell engineering platform Solupore®. With consortium partners Bluebridge Technologies and NIBRT, the project expands Avectas development towards commercialising an advanced large-scale, digitalised cell engineering platform optimised to manufacture off-the-shelf cell-based therapies for cancer treatment.
The Disruptive Technologies Innovation Fund (DTIF) is a €500 million fund established under Project Ireland 2040 and run by the Department of Enterprise Trade and Employment with support from Enterprise Ireland.
BlueBridge: The great Irish medtech engineers you haven’t heard of
Garret Coady, BlueBridge Technologies CEO, demonstrating the Resper device. Image: Jason Clarke Photography
Since 2006, BlueBridge Technologies has been working behind the scenes of the world’s biggest medtech companies. Now, it’s stepping into the limelight.
If you know medical devices, you will know Medtronic and Boston Scientific. If you are, like these, a company developing medical devices, you will know BlueBridge Technologies.
Operating somewhat in the shadow of the corporate giants it services, this Irish company designs and builds devices specifically for the tightly regulated health space. Its clients include the aforementioned Medtronic and Boston Scientific, as well as US multinational Abbott Laboratories and Swiss pharma company Novartis.